08/19/15 - 10:30 AM EDT
Speculative biotech stocks that were huge winners for healthcare investors earlier this year are now down significantly from their 52-week highs.
08/07/15 - 06:10 AM EDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
08/04/15 - 11:25 AM EDT
RBC Capital analyst Michael Yee offers seven reasons why Biomarin Pharmaceuticals will secure U.S. approval for drisapersen to treat Duchenne muscular dystrophy, a rare, genetic muscle-wasting disease.
07/31/15 - 09:36 AM EDT
Investors asking Intra-Cellular for a copy of the scientific poster needed to conduct proper due diligence on ITI-007 are told they can't have it.
07/30/15 - 11:03 AM EDT
The only saving grace is that no one, not even the most Kool-Aid-drinking MannKind supporter, is surprised by Afrezza's poor sales.
07/29/15 - 10:33 AM EDT
MannKind isn't at risk of shutting down imminently because of the death-spiral convert, but the company was forced into a weakened negotiating position because Afrezza is selling poorly.
07/28/15 - 04:15 PM EDT
Gilead Sciences will not be blamed for a cooling of the biotech bull market, if any such thing exists.
07/28/15 - 10:23 AM EDT
It's a day that ends in "day," which means cancer immunotherapy is dominating the biotech news.
07/27/15 - 12:42 PM EDT
Investor confidence in biotech stocks is shaky following last week's Biogen blow-up, making Tuesday's Gilead earnings even more important.
07/27/15 - 10:30 AM EDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?